Skip to content
N1 Life
All Insights

Research & Industry

PP405 Moves Hair-Follicle Regeneration Into a Larger Trial

Pelage has begun a phase 2/3 study of topical PP405 in men with androgenetic alopecia.

  • hair follicles
  • topical therapy
  • clinical development

A different target in hair-loss research

In October 2026, Pelage Pharmaceuticals announced the first participant had received PP405 in AWAKEN, a phase 2/3 study for men with androgenetic alopecia. The investigational topical gel is designed to reactivate dormant hair-follicle stem cells by acting on a metabolic pathway. [1]

Existing treatments address hair loss through different mechanisms. PP405 brings another question to clinical development: can a topical medicine influence the activity of follicle stem cells and produce meaningful hair growth in a larger patient population?

From an early signal to a larger study

Pelage’s phase 2a randomized study enrolled 78 men and women with androgenetic alopecia. Participants applied PP405 or vehicle once daily for four weeks and were followed through week 12. Safety was the primary endpoint; hair growth was assessed through exploratory endpoints. [2]

The company reported that, among men with a higher degree of hair loss, 31% of those receiving PP405 had more than a 20% increase in hair density at week eight, compared with 0% in the vehicle group. Pelage did not disclose the number of people in each arm of that subgroup in its announcement. [2]

AWAKEN is designed to provide a broader assessment. The randomized, double-blind, vehicle-controlled study plans to enroll about 600 adult men. Its main efficacy measure is the change in non-vellus hair count in a target area at week 24, with follow-up for longer-term safety. Pelage reported first dosing in October; results are still ahead. A separate phase 2 trial in women with androgenetic alopecia was listed as recruiting in a registry update posted on November 17, 2026. [1, 3, 5]

Developing for the scalp

A hair-follicle program must connect biology with a treatment that can be applied consistently. Formulation, exposure at the relevant scalp site, tolerability and the length of treatment all influence the questions a development team needs to answer.

Pelage’s approach makes the follicle’s own regenerative biology the focus of a new clinical program. The larger study will show how the early signal develops when the treatment is evaluated over a longer period and in a defined group of patients.

Sources

  1. Pelage Pharmaceuticals. First patient dosed in the AWAKEN PP405 trial. October 14, 2026.
  2. Pelage Pharmaceuticals. PP405 phase 2a trial results. June 17, 2025.
  3. ClinicalTrials.gov. AWAKEN study, NCT07819435.
  4. N1 Life. PP405毛囊再生药物进入大规模临床验证. WeChat, November 6, 2026.
  5. ClinicalTrials.gov. PP405 phase 2 study in women, NCT07907783.